Recent advances in selective opioid receptor agonists and antagonists.
about
Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesicsKappa opioid antagonists: past successes and future prospectsKappa opioids as potential treatments for stimulant dependenceHerkinorin analogues with differential beta-arrestin-2 interactionsEarly life programming of pain: focus on neuroimmune to endocrine communicationMolecular switches of the κ opioid receptor triggered by 6'-GNTI and 5'-GNTI.Structure of the δ-opioid receptor bound to naltrindoleSalvinorin A analogs as probes in opioid pharmacology.Ligand/kappa-opioid receptor interactions: insights from the X-ray crystal structure.Investigation of the interaction between the atypical agonist c[YpwFG] and MOR.Identification, structure-activity relationships and molecular modeling of potent triamine and piperazine opioid ligands.Delta opioid receptor on equine sperm cells: subcellular localization and involvement in sperm motility analyzed by computer assisted sperm analyzer (CASA).Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.Design, synthesis, and validation of a β-turn mimetic library targeting protein-protein and peptide-receptor interactionsComprehensive peptidomimetic libraries targeting protein-protein interactions.Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2.Opioid induced hyperalgesia in anesthetic settings.Homology modeling of opioid receptor-ligand complexes using experimental constraintsSynthesis of Carfentanil Amide Opioids Using the Ugi Multicomponent Reaction.State-dependent opioid control of pain.Semisynthetic neoclerodanes as kappa opioid receptor probes.Characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as novel leads to development of mu opioid receptor selective antagonists.Receptor Reserve Moderates Mesolimbic Responses to Opioids in a Humanized Mouse Model of the OPRM1 A118G PolymorphismOpioid activity of spinally selective analogues of N-naphthoyl-β-naltrexamine in HEK-293 cells and mice.Discovery of 5-substituted tetrahydronaphthalen-2yl-methyl with N-phenyl-N-(piperidin-4-yl)propionamide derivatives as potent opioid receptor ligands.Synthesis and characterization of a dual kappa-delta opioid receptor agonist analgesic blocking cocaine reward behaviorImproving metabolic stability by glycosylation: bifunctional peptide derivatives that are opioid receptor agonists and neurokinin 1 receptor antagonistsHeteroatom analogues of hydrocodone: synthesis and biological activityThe importance of micelle-bound states for the bioactivities of bifunctional peptide derivatives for delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: application of the 'message-address' concept in development of mMorphine as a Potential Oxidative Stress-Causing Agent.Allosteric modulation model of the mu opioid receptor by herkinorin, a potent not alkaloidal agonist.Binding mode analyses of NAP derivatives as mu opioid receptor selective ligands through docking studies and molecular dynamics simulation.Targeting multiple opioid receptors - improved analgesics with reduced side effects?Differential helical orientations among related G protein-coupled receptors provide a novel mechanism for selectivity. Studies with salvinorin A and the kappa-opioid receptor.Rapid access to morphinones: removal of 4, 5-ether bridge with Pd-catalyzed triflate reduction.On the Role of Cannabinoid CB1- and μ-Opioid Receptors in Motor Impulsivity.Design synthesis and structure-activity relationship of 5-substituted (tetrahydronaphthalen-2yl)methyl with N-phenyl-N-(piperidin-2-yl)propionamide derivatives as opioid ligands14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies.[6,7]-heterocycle-fused 14-hydroxymorphinan derivatives: design, synthesis, and opioid receptor activity.
P2860
Q24647687-ECFEFFC1-4740-4A48-87EA-1EB64E09897DQ24647830-2B547454-9B96-4CB5-BDC9-C9BB20A6E803Q24647849-D054C27D-B2C9-420C-9F21-4B0B7ABF5BEFQ24649793-E698E03E-7362-4412-BB02-7C916AEF8154Q26751421-36077BC5-83D2-4DC0-9CA6-980F910F86D9Q27302413-9F7212E3-A13F-4E97-9A2F-9086FB9FAD5AQ27679153-73B16DE7-F265-42CF-AEB2-1C3D5C8AB7C5Q30439719-B70E73BC-79E0-49FC-8180-39D9D61FFBA6Q30544924-82872722-3792-48D1-8507-F833D2667513Q31151838-087ECBA0-78A7-4609-BB9F-BBD04DD6476FQ33478179-E0C98742-122D-42EB-B0FF-C00A5FB33B8EQ33616823-B22A8CEE-0BF8-4E93-AAE6-19DB2E7CF849Q33893723-7B5F3D13-2C21-42C3-ABDB-93BF5C1D49DEQ33910319-FB5D0AD3-7F4B-46B7-B26E-295ED00C7558Q34338569-C3B025B3-D586-45B4-A624-BB6DB839D4DCQ34538336-C557346D-2466-4196-BFA8-D52843DEBCAAQ34613490-8801A1FD-8551-4419-BEF9-5C1E7D6A3F3AQ34651393-FA087412-6B29-41AE-8F86-6EFB4E68DAADQ35684498-C0AE453F-8CF9-45B2-9B8E-673BB3AE15CBQ35811910-46AC289C-7CAC-490C-B3A3-2E1E818B9A0DQ35935443-8B7BEFFE-0609-45D6-A69C-3B9E4FF886EBQ36015414-43D0C078-F56A-4ED7-9D8D-EE0DEA61538CQ36059914-22C842C1-6C44-4723-925A-BCA2E35DC85DQ36225640-E08C8CC5-773D-40D9-98DB-B666C0605A0CQ36274625-5F6FBCC7-846A-4866-B0D1-431FB9A27F58Q36296493-FECE643B-BDE2-4E67-912D-D008DAF14460Q36464821-B8414170-8652-417E-8DCC-64E13A19B794Q36745642-88576C8F-176E-47B0-A0E0-F7D8C3DC5CD5Q37176219-D0A01A2E-9BEE-48F8-92C2-4C7E5B6D0573Q37317909-5C777DC4-7097-43CD-9C54-69E106761048Q38174596-8912A5F5-906A-44FE-90CD-0D8817A5EB8FQ38736870-63FD0D43-46D1-438E-8CBA-E9251AA61074Q38743944-558772E2-111E-40E5-A5C9-A6620C16B07CQ39221109-B485ECE2-2D7C-4D3A-96CA-E6597810E384Q40205429-46B5581A-778B-4219-828C-A2AB4DAFDABEQ40632677-6C0D30A5-977B-4901-AAD6-9E95706CA768Q41811043-58C9AE68-6E50-4E51-86D8-E006CEF76E82Q42183675-C1E0B2D4-5606-409F-A0B6-E2F22C55FDF8Q42942034-916C91EF-5FFB-4A75-8B70-4450B0EB0B6CQ43256896-930DC6C7-10E4-4A3E-8A57-EB2AB98E699A
P2860
Recent advances in selective opioid receptor agonists and antagonists.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Recent advances in selective opioid receptor agonists and antagonists.
@ast
Recent advances in selective opioid receptor agonists and antagonists.
@en
type
label
Recent advances in selective opioid receptor agonists and antagonists.
@ast
Recent advances in selective opioid receptor agonists and antagonists.
@en
prefLabel
Recent advances in selective opioid receptor agonists and antagonists.
@ast
Recent advances in selective opioid receptor agonists and antagonists.
@en
P2860
P356
P1476
Recent advances in selective opioid receptor agonists and antagonists.
@en
P2093
Masakatsu Eguchi
P2860
P304
P356
10.1002/MED.10059
P577
2004-03-01T00:00:00Z